In case of diagnosis of COVID-19: According to ECDC recommendations, patients ought to be deferred for at least three months. However, this is not always possible due to the risk from the underlying disease. Therefore, in patients with high risk disease, a stem cell transplant should be deferred until the patient is asymptomatic and has three repeated virus PCR negativity at least one week apart. In patients with low-risk disease a three-month HCT deferral is recommended.

In case of symptoms of an acute respiratory tract infection (fever, cough or other symptoms attributed to viral respiratory infections), patients shall be tested for respiratory viral infections preferably by multiplex PCR and depending on which virus is detected, deferral of HCT should be considered. 

In case of close contact with a person diagnosed for COVID-19 any transplant procedures (PBSC mobilization, BM harvest, conditioning) shall not be performed within at least 14 preferably 21 days from the last contact. Patient should be closely monitored for the presence of COVID-19, with confirmed PCR negativity. 

 Stem cell transplant patients should refrain from non-necessary travel to areas designated as high-risk areas by the WHO.

In case of travel to a high-risk area or a close contact with person travelling from a high-risk area for COVID-19 (as defined by health authorities*), any transplant procedures (PBSC mobilization, BM harvest, conditioning) should not be performed within at least 14 preferably 21 days from the last contact. 

Prepared by: Jan Styczynski, Malgorzata Mikulska, Per Ljungman
Approved by: Nicolaus Kröger, Rafael Duarte, Harry Dolstra, Andreu Gusi
EBMT, 1 March 2020